UNIVERSITY OF SOUTHERN CALIFORNIA
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1880-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://startusc.com
In-Utero Endoscopic Correction of Spina Bifida
- Conditions
- Neural Tube DefectsSpina BifidaMyelomeningocele
- Interventions
- Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization TechniqueDevice: In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 110
- Registration Number
- NCT04362592
- Locations
- 🇺🇸
Wellington Regional Medical Center, Wellington, Florida, United States
🇺🇸Hollywood Presbyterian Medical Center, Los Angeles, California, United States
Duration of Urinary Catheterization
- Conditions
- Colorectal Surgery
- Interventions
- Other: Urinary catheter removal on postoperative day 3Other: Urinary catheter removal on postoperative day 1
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 176
- Registration Number
- NCT04359069
- Locations
- 🇺🇸
Keck Hospital of USC, Los Angeles, California, United States
🇺🇸Los Angeles County Hospital (LAC/USC), Los Angeles, California, United States
Diaphragmatic Breathing Exercises in Total Knee Arthroplasty Patients
- Conditions
- Anesthesia and Analgesia
- Interventions
- Behavioral: Diaphragmatic Breathing
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 50
- Registration Number
- NCT04336579
- Locations
- 🇺🇸
Keck Hospital of USC, Los Angeles, California, United States
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
- Conditions
- Triple NegativeMetastaticDisseminated Tumor CellBreastCancer
- Interventions
- Combination Product: Sarilumab 150mg or 200 mg plus CapecitabineCombination Product: Sarilumab 150mg plus Capecitabine
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 65
- Registration Number
- NCT04333706
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸UF Health, Gainesville, Florida, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Telemedicine Monitoring of Nocturnal Incidents
- Conditions
- Diabetes Mellitus, Type 1Hypoglycemia
- Interventions
- Other: CGM-Tele-monitoring
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 10
- Registration Number
- NCT04328896
- Locations
- 🇺🇸
USC Westside Center for Diabetes, Los Angeles, California, United States
Pilot Sugar Reduction Intervention in Kiritimati Teenagers
- Conditions
- Type 2 DiabetesObesity
- Interventions
- Behavioral: Sugar-reduction intervention
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 63
- Registration Number
- NCT04319003
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇰🇮Kiritimati, London Village, Kiribati
An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer
- Conditions
- Stage IIIA Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8Non-Metastatic Prostate CarcinomaStage I Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8
- Interventions
- Procedure: 7 Tesla Magnetic Resonance Imaging
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 20
- Registration Number
- NCT04318028
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
- Conditions
- Resectable Skin Squamous Cell CarcinomaStage I Skin CancerRecurrent Skin Squamous Cell CarcinomaStage II Skin CancerStage III Skin Cancer
- Interventions
- Procedure: Resection
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 34
- Registration Number
- NCT04315701
- Locations
- 🇺🇸
University of Nebraska, Omaha, Nebraska, United States
🇺🇸Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Prospective Study of Induction Medications Used in the Trauma RSI
- Conditions
- TraumaRapid Sequence Intubation
- Interventions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 7000
- Registration Number
- NCT04291521
- Locations
- 🇺🇸
Keck School of Medicine of the University of Southern California, Los Angeles, California, United States
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 30
- Registration Number
- NCT04284657
- Locations
- 🇺🇸
Keck School of Medicine of University of Southern California, Los Angeles, California, United States